Clinical Trial Update: Myositis Interstitial Lung Disease Nintedanib Trial [Phase 4]

View source ↗

Summary

This clinical trial update notes that a Phase 4 study of nintedanib for myositis-associated interstitial lung disease (MA-ILD) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myositis-associated Interstitial Lung Disease

Drugs mentioned

• Nintedanib (nintedanib)

Snippet

Sponsor: Rohit Aggarwal, MD | Conditions: Myositis Associated Interstitial Lund Disease (MA-ILD) | Phase 4 | Status: COMPLETED